Physician

Ketan S. Shah, MD

According to 2025 Medicare claims, Ketan Shah, MD (NPI: 1083664023) practices hematology/oncology in the Dayton-Kettering-Beavercreek, OH market, with the plurality of this provider's patient population coming from Montgomery, OH. This provider's primary affiliated billing organization is DAYTON PHYSICIANS, LLC (NPI: 1902844947; TIN: 203130844) and primary practice location at 45409-1328. Shah is affiliated with the Health Centers of Ohio ACO LLC (ACO ID: A5411), participating under the MSSP model.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 497 traditional Medicare patients, billed 106,519 HCPCS/CPT codes, and received $2,284,853 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 638 prescription claims across 126 beneficiaries totaling $2,511,446 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2019 DME data shows 47 claims. Open Payments data shows 79 records totaling $1,685. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,365,489 and ending at $2,284,853. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,202,206 to $2,511,446. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	497	116,831	$1,365,489
2016	512	118,259	$1,467,697
2017	591	138,420	$1,922,491
2018	664	127,471	$1,978,651
2019	617	82,056	$1,413,904
2020	538	89,807	$1,576,646
2021	543	87,694	$1,752,210
2022	543	95,923	$1,629,434
2023	446	90,860	$1,302,872
2024	497	106,519	$2,284,853

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	192	1,037	$1,202,206
2016	153	924	$1,379,508
2017	159	872	$935,174
2018	145	717	$989,441
2019	105	567	$905,868
2020	122	678	$1,509,855
2021	131	672	$2,291,816
2022	122	611	$1,856,534
2023	115	541	$2,217,961
2024	126	638	$2,511,446

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	45	$1,691
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	47	$25,422
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	74	229	$132
96413	Administration of chemotherapy into vein, 1 hour or less	84	267	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	157	263	$86
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	198	501	$12
96372	Injection of drug or substance under skin or into muscle	64	149	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	21	630	$362,237
Calquence	Acalabrutinib Maleate	20	600	$303,936
Imbruvica	Ibrutinib	16	448	$260,660
Revlimid	Lenalidomide	14	392	$250,132
Xtandi	Enzalutamide	15	450	$204,606

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	79	$1,685	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ketan S. Shah, MD?

Tedicare shows public-source Medicare data for Ketan S. Shah, MD (NPI 1083664023), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ketan S. Shah, MD have ACO affiliation data?

Ketan S. Shah, MD is shown with ACO affiliation data for Health Centers of Ohio ACO LLC (MSSP, ACO ID A5411).

What billing organization is linked to Ketan S. Shah, MD?

Ketan S. Shah, MD is linked to DAYTON PHYSICIANS, LLC (billing NPI 1902844947) in the available physician profile data.

Does Ketan S. Shah, MD have Open Payments data?

Ketan S. Shah, MD has 79 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.